IMMUNOKINASES - Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges - page 326

binding protein alpha expression in acute myeloid leukemia.
Cancer Res. 68, 3142-3151.
43. Friedmann T. (1992) Gene therapy of cancer through restora-
tion of tumor-suppressor functions? Cancer 70, 1810-1817.
44. Bowen C, Spiegel S, Gelmann EP. (1998) Radiation-induced
apoptosis mediated by retinoblastoma protein. Cancer Res. 58,
3275-3281.
45. Levine AJ, Wu MC, Chang A, Silver A, Attiyeh EF, Lin J,
et al. (1995) The spectrum of mutations at the p53 locus.
Evidence for tissue-specific mutagenesis, selection of mutant
alleles, and a “gain of function” phenotype. Ann. N Y Acad.
Sci. 768, 111-128.
46. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm
J, Lintault L, et al. (2007) Restoration of p53 function leads to
tumor regression in vivo. Nature 445, 661-665.
47. Capdeville R, Buchdunger E, Zimmermann J, Matter A. (2002)
Glivec (STI571, imatinib), a rationally developed, targeted
anticancer drug. Nat. Rev. Drug. Discov. 1, 493-502.
48. Pagano L, Fianchi L, Caira M, Rutella S, Leone G. (2007) The
role of Gemtuzumab Ozogamicin in the treatment of acute
myeloid leukemia patients. Oncogene 26, 3679-3690.

49. Kreitman RJ. (2004) Confirmation and prevention of targeted
toxicity by a recombinant fusion toxin. Mol. Cancer Ther. 3,
1691-1692.
50. Barth S, Tur MK, Stocker M, Fischer R. (2005) Immunoki-
nases. EP 1704228 (A2).
51. Smith CA, Gruss HJ, Davis T, Anderson D, Farrah T, Baker E,
et al. (1993) CD30 antigen, a marker for Hodgkin's lymphoma,
is a receptor whose ligand defines an emerging family of
cytokines with homology to TNF. Cell 73, 1349-1360.
52. Herszfeld D, Wolvetang E, Langton-Bunker E, Chung TL,
Filipczyk AA, Houssami S, et al. (2006) CD30 is a survival
factor and a biomarker for transformed human pluripotent stem
cells. Nat. Biotechnol. 24, 351-357.
53. Klimm B, Schnell R, Diehl V, Engert A. (2005) Current
treatment and immunotherapy of Hodgkin's lymphoma.

Haematologica 90, 1680-1692.
54. Barth S, Huhn M, Matthey B, Tawadros S, Schnell R,
Schinkothe T, et al. (2000) Ki-4(scFv)-ETA', a new recombi-
nant anti-CD30 immunotoxin with highly specific cytotoxic
activity against disseminated Hodgkin tumors in SCID mice.
Blood 95, 3909-3914.